Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Solid Tumour: early-phase trial registry
1 of 4 indexed Malignant Solid Tumour trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Malignant Solid Tumour: 4 US clinical trials tracked, 1 recruiting.
Malignant Solid Tumour is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Altor BioScience, running 1 of these trials.
Enrollment posture brief
Registry condition malignant-solid-tumour
OPEN 1 | RECR 25% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Malignant Solid Tumour lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Solid Tumour on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Solid Tumour is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
NCT07044336
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations
NCT01611857
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
NCT01325558
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
University of Colorado, Denver
NCT00551096
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Solid Tumour records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Solid Tumour trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Solid Tumour page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Malignant Solid Tumour trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Altor BioScience sponsors the most Malignant Solid Tumour trials on record, review their full trial history before evaluating a specific study. See Altor BioScience's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Solid Tumour condition card totals 4 registered trials; most-linked intervention ZD6474; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.